Charles River Laboratories International Inc tiene un precio objetivo de consenso de $201.12 basado en las calificaciones de 21 analistas. El máximo es $275, emitido por Wells Fargo el septiembre 22, 2023. El mínimo es $165, emitido por JP Morgan el noviembre 6, 2025. Las 3 calificaciones de analistas más recientes fueron publicadas por Morgan Stanley, TD Cowen y JP Morgan el noviembre 11, 2025, noviembre 10, 2025 y noviembre 6, 2025, respectivamente. Con un precio objetivo promedio de $182.33 entre Morgan Stanley, TD Cowen y JP Morgan, hay una 5.09% upside implícita para Charles River Laboratories International Inc según estas calificaciones más recientes de analistas.
1calculado a partir de las calificaciones de los analistas
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/11/2025 | 6.63% | Morgan Stanley | $170 → $185 | Maintains | Equal-Weight | |||
11/10/2025 | 13.54% | TD Cowen | $205 → $197 | Maintains | Buy | |||
11/06/2025 | -4.9% | JP Morgan | $160 → $165 | Maintains | Neutral | |||
11/06/2025 | 21.04% | Barclays | $195 → $210 | Maintains | Overweight | |||
11/06/2025 | 14.7% | Baird | $178 → $199 | Upgrade | Neutral → Outperform | |||
10/17/2025 | 0.29% | Mizuho | $155 → $174 | Maintains | Neutral | |||
10/06/2025 | — | William Blair | — | Upgrade | Market Perform → Outperform | |||
10/03/2025 | 15.27% | Evercore ISI Group | $190 → $200 | Maintains | Outperform | |||
10/02/2025 | 12.39% | Barclays | $165 → $195 | Upgrade | Equal-Weight → Overweight | |||
09/09/2025 | 12.39% | Jefferies | $142 → $195 | Upgrade | Hold → Buy | |||
08/08/2025 | 9.51% | Evercore ISI Group | $180 → $190 | Maintains | Outperform | |||
08/07/2025 | -7.78% | JP Morgan | $145 → $160 | Maintains | Neutral | |||
08/07/2025 | -4.9% | Barclays | $155 → $165 | Maintains | Equal-Weight | |||
07/09/2025 | 3.75% | Evercore ISI Group | $170 → $180 | Maintains | Outperform | |||
07/09/2025 | 15.27% | Citigroup | $150 → $200 | Upgrade | Neutral → Buy | |||
05/23/2025 | 4.9% | Redburn Atlantic | $188 → $182 | Upgrade | Neutral → Buy | |||
05/08/2025 | -10.66% | Barclays | $145 → $155 | Maintains | Equal-Weight | |||
05/08/2025 | -19.31% | Baird | $118 → $140 | Maintains | Neutral | |||
04/10/2025 | -16.43% | Barclays | $160 → $145 | Maintains | Equal-Weight | |||
04/09/2025 | -10.66% | Mizuho | $175 → $155 | Maintains | Neutral | |||
03/21/2025 | -2.02% | Goldman Sachs | $190 → $170 | Downgrade | Buy → Neutral | |||
03/04/2025 | 0.86% | Citigroup | $155 → $175 | Upgrade | Sell → Neutral | |||
03/03/2025 | 8.36% | Redburn Atlantic | $171 → $188 | Upgrade | Sell → Neutral | |||
02/20/2025 | -4.9% | JP Morgan | $175 → $165 | Maintains | Neutral | |||
02/20/2025 | -0.29% | Baird | $177 → $173 | Maintains | Neutral | |||
02/20/2025 | -7.78% | Barclays | $166 → $160 | Maintains | Equal-Weight | |||
02/18/2025 | -4.32% | Barclays | $205 → $166 | Maintains | Equal-Weight | |||
02/05/2025 | 6.05% | Morgan Stanley | $220 → $184 | Maintains | Equal-Weight | |||
02/03/2025 | 0.86% | JP Morgan | $215 → $175 | Maintains | Neutral | |||
01/23/2025 | 9.51% | Goldman Sachs | $220 → $190 | Maintains | Buy | |||
01/22/2025 | — | William Blair | — | Downgrade | Outperform → Market Perform | |||
01/17/2025 | 6.63% | UBS | $250 → $185 | Downgrade | Buy → Neutral | |||
01/14/2025 | — | William Blair | — | Reiterates | Outperform → Outperform | |||
12/16/2024 | 26.8% | Morgan Stanley | $225 → $220 | Maintains | Equal-Weight | |||
12/13/2024 | 21.04% | B of A Securities | $220 → $210 | Maintains | Neutral | |||
11/11/2024 | 30.84% | TD Cowen | $203 → $227 | Maintains | Hold | |||
11/07/2024 | 44.09% | UBS | $240 → $250 | Maintains | Buy | |||
11/07/2024 | 29.68% | Evercore ISI Group | $190 → $225 | Maintains | In-Line | |||
10/23/2024 | -3.75% | CLSA | — | → $167 | Initiates | → Underperform | ||
10/16/2024 | 18.16% | Barclays | $210 → $205 | Maintains | Equal-Weight | |||
10/14/2024 | -12.97% | Redburn Atlantic | → $151 | Initiates | → Sell | |||
10/07/2024 | 9.51% | Evercore ISI Group | $225 → $190 | Downgrade | Outperform → In-Line | |||
10/02/2024 | 23.92% | B of A Securities | $250 → $215 | Downgrade | Buy → Neutral | |||
10/01/2024 | 0.86% | Citigroup | $215 → $175 | Downgrade | Neutral → Sell | |||
09/20/2024 | 9.51% | Baird | $191 → $190 | Maintains | Neutral | |||
08/12/2024 | 17% | TD Cowen | $228 → $203 | Maintains | Hold | |||
08/08/2024 | 23.92% | Morgan Stanley | $235 → $215 | Maintains | Equal-Weight | |||
08/08/2024 | 21.04% | Barclays | $230 → $210 | Maintains | Equal-Weight | |||
08/08/2024 | 38.33% | UBS | $290 → $240 | Maintains | Buy | |||
08/08/2024 | 29.68% | Evercore ISI Group | $265 → $225 | Maintains | Outperform | |||
08/08/2024 | 44.09% | Goldman Sachs | $290 → $250 | Maintains | Buy | |||
08/08/2024 | 18.16% | JP Morgan | $270 → $205 | Downgrade | Overweight → Neutral | |||
08/08/2024 | 10.09% | Baird | $239 → $191 | Downgrade | Outperform → Neutral | |||
07/10/2024 | 37.75% | Baird | $271 → $239 | Maintains | Outperform | |||
06/28/2024 | 32.56% | Barclays | → $230 | Initiates | → Equal-Weight | |||
06/28/2024 | — | Argus Research | — | Downgrade | Buy → Hold | |||
06/07/2024 | 35.45% | Mizuho | → $235 | Initiates | → Neutral | |||
06/06/2024 | 67.15% | Goldman Sachs | → $290 | Initiates | → Buy | |||
05/13/2024 | 31.41% | TD Cowen | $260 → $228 | Maintains | Hold | |||
05/10/2024 | 55.62% | Baird | $282 → $270 | Maintains | Outperform | |||
03/18/2024 | 67.15% | Argus Research | $240 → $290 | Maintains | Buy | |||
02/15/2024 | 61.38% | JP Morgan | $270 → $280 | Maintains | Overweight | |||
02/15/2024 | 52.74% | Evercore ISI Group | $260 → $265 | Maintains | Outperform | |||
02/15/2024 | 67.15% | UBS | $270 → $290 | Maintains | Buy | |||
02/15/2024 | 44.09% | Citigroup | $215 → $250 | Maintains | Neutral | |||
02/15/2024 | 54.47% | Baird | $252 → $268 | Maintains | Outperform | |||
02/15/2024 | — | Guggenheim | — | Downgrade | Buy → Neutral | |||
12/20/2023 | 55.62% | JP Morgan | $210 → $270 | Maintains | Overweight | |||
12/11/2023 | 23.92% | Citigroup | $190 → $215 | Maintains | Neutral | |||
11/10/2023 | 18.16% | Morgan Stanley | $220 → $205 | Maintains | Equal-Weight | |||
11/09/2023 | 23.92% | UBS | $250 → $215 | Maintains | Buy | |||
10/24/2023 | 26.8% | Morgan Stanley | $235 → $220 | Maintains | Equal-Weight | |||
09/25/2023 | 20.46% | TD Cowen | $212 → $209 | Maintains | Market Perform | |||
09/22/2023 | 47.55% | Baird | $267 → $256 | Maintains | Outperform | |||
09/22/2023 | 29.68% | Guggenheim | $255 → $225 | Maintains | Buy | |||
09/22/2023 | 58.5% | Wells Fargo | $280 → $275 | Maintains | Overweight | |||
09/13/2023 | 22.19% | TD Cowen | → $212 | Initiates | → Market Perform | |||
08/10/2023 | 44.09% | JP Morgan | $225 → $250 | Maintains | Overweight | |||
08/10/2023 | 41.21% | B of A Securities | $235 → $245 | Maintains | Buy | |||
07/11/2023 | 29.68% | Citigroup | $260 → $225 | Downgrade | Buy → Neutral | |||
07/10/2023 | 29.68% | Citigroup | $260 → $225 | Downgrade | Buy → Neutral | |||
05/15/2023 | 29.68% | Morgan Stanley | $230 → $225 | Maintains | Equal-Weight | |||
05/12/2023 | 46.97% | Credit Suisse | $260 → $255 | Maintains | Outperform | |||
05/12/2023 | 61.38% | Wells Fargo | $290 → $280 | Maintains | Overweight | |||
03/28/2023 | 17% | Jefferies | $233 → $203 | Maintains | Hold | |||
02/23/2023 | 49.86% | Credit Suisse | $280 → $260 | Maintains | Outperform | |||
02/23/2023 | 32.56% | Morgan Stanley | $241 → $230 | Maintains | Equal-Weight | |||
02/23/2023 | 49.86% | Citigroup | $280 → $260 | Maintains | Buy | |||
02/23/2023 | 46.97% | Guggenheim | → $255 | Upgrade | Neutral → Buy | |||
01/12/2023 | — | Jefferies | — | Downgrade | Buy → Hold | |||
01/11/2023 | 64.27% | Baird | $275 → $285 | Maintains | Outperform |
El último precio objetivo de Charles River (NYSE:CRL) fue comunicado por Morgan Stanley el noviembre 11, 2025. La firma de analistas fijó un precio objetivo para $185.00 que espera CRL a rise dentro de 12 meses (un posible 6.63% upside). 35 firmas de analistas han reportado calificaciones en el último año.
La última calificación de analistas para Charles River (NYSE:CRL) fue proporcionada por Morgan Stanley, y Charles River mantuvo su equal-weight calificación.
La última revisión al alza de Charles River Laboratories International Inc se produjo en noviembre 6, 2025, cuando Baird elevó su precio objetivo a $199. Baird anteriormente tenía a neutral para Charles River Laboratories International Inc.
La última revisión a la baja de Charles River Laboratories International Inc se produjo en marzo 21, 2025, cuando Goldman Sachs cambió su precio objetivo de $190 a $170 para Charles River Laboratories International Inc.
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Charles River, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Charles River se registró el noviembre 11, 2025, por lo que la próxima calificación estará disponible en torno al noviembre 11, 2026.
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Charles River (CRL) fue un mantuvo con un precio objetivo de $170.00 a $185.00. El precio actual al que cotiza Charles River (CRL) es de $173.50, que es within del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.